GRCE (Grace Therapeutics) Buyback Yield %: 0.00 (As of Jun. 30, 2026)


GRCE Grace Therapeutics Inc GRCE
33 GF Score
Price $2.29
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Buyback Yield %?

Grace Therapeutics GRCE -2.13% 33 Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus rates GRCE with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 742 Biotechnology companies, Grace Therapeutics ranks worse than 134770.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Grace Therapeutics's current buyback yield was 0.00%.

Grace Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Buyback Yield % Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.48 -23.30 -47.96 0.00

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.96 0.00 0.00 0.00 0.00

GRCE vs INMB, ABVC, NTRB: Buyback Yield % Comparison

For the Biotechnology subindustry, Grace Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grace Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Buyback Yield % falls into.


GRCE
33GF Score
Grace Therapeutics Inc GRCE
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Grace Therapeutics's Buyback Yield for the fiscal year that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 74.19112
=0.00%

Grace Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 74.19112
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Grace Therapeutics (GRCE) has a Buyback Yield % of 0.00 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Grace Therapeutics and its competitors. According to the industry distribution chart, Grace Therapeutics ranks #999999 out of 742 companies in the Biotechnology industry.
Is Grace Therapeutics' Buyback Yield % too high?
Grace Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Grace Therapeutics ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Grace Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Buyback Yield % compare to INMB and ABVC?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #999999 out of 742 companies for Buyback Yield %. This places Grace Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Grace Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
33GF Score

Get the complete analysis for GRCE

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.29
Price